Vascular Biogenics (VBLT) Rating Lowered to Market Perform at JMP Securities
A number of other equities research analysts also recently weighed in on VBLT. Piper Jaffray Companies downgraded Vascular Biogenics from an overweight rating to a neutral rating and set a $4.00 target price on the stock. in a report on Thursday. HC Wainwright downgraded Vascular Biogenics from a buy rating to a neutral rating and set a $3.00 target price on the stock. in a report on Thursday. ValuEngine raised Vascular Biogenics from a sell rating to a hold rating in a report on Friday, February 2nd. Finally, Zacks Investment Research downgraded Vascular Biogenics from a hold rating to a sell rating in a report on Friday, February 23rd. Two research analysts have rated the stock with a sell rating and four have assigned a hold rating to the stock. The company presently has a consensus rating of Hold and a consensus price target of $3.33.
Shares of Vascular Biogenics (NASDAQ VBLT) opened at $2.60 on Thursday. The firm has a market capitalization of $77.28, a price-to-earnings ratio of -3.29 and a beta of -2.44. Vascular Biogenics has a twelve month low of $2.30 and a twelve month high of $9.05.
COPYRIGHT VIOLATION NOTICE: “Vascular Biogenics (VBLT) Rating Lowered to Market Perform at JMP Securities” was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another publication, it was stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://www.thecerbatgem.com/2018/03/12/vascular-biogenics-vblt-rating-lowered-to-market-perform-at-jmp-securities.html.
Vascular Biogenics Company Profile
Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels.
Receive News & Ratings for Vascular Biogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics and related companies with MarketBeat.com's FREE daily email newsletter.